Adam Laponis, Chief Financial Officer of Twist Bioscience Corp (NASDAQ:TWST), executed a transaction involving the disposition of 2,399 shares of the company’s common stock on July 9, 2026, according to a recent SEC filing. The sale generated proceeds totaling $226,307. The timing of this transaction coincides with a period of price depreciation for TWST, which has declined 9.3% over the preceding week. At the time of the sale, the stock was trading at $90.35, while the execution price for the shares was recorded at $94.334.
According to data provided by InvestingPro, TWST exhibits characteristics of overvaluation at its current price point. The stock’s beta stands at 2.11, a metric that reflects high volatility within the market. This elevated beta suggests that TWST’s price movements are significantly more pronounced than the broader market, a factor that can influence executive compensation structures and tax withholding calculations.
The transaction executed by Mr. Laponis was classified as a "sell to cover" event. This designation indicates that the sale was not a discretionary trade driven by personal investment strategy. Instead, it was mandated by the company’s equity incentive plans to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units. Such mandatory dispositions are standard operational procedures designed to fund tax liabilities for employees receiving equity-based compensation.
Following the completion of this transaction, Mr. Laponis’s direct ownership of Twist Bioscience common stock stands at 110,276 shares. This remaining balance provides a baseline for monitoring future insider activity and potential shifts in executive confidence.
In the broader context of market analysis, Twist Bioscience has attracted attention from multiple analyst firms, each highlighting the company’s potential within the biotechnology sector. The company reported second-quarter revenue of $111 million, representing a 19% increase year-over-year. This financial result surpassed the consensus estimate of $108 million, demonstrating operational strength in revenue generation.
TD Cowen responded to this revenue beat by raising its price target for Twist Bioscience from $58 to $68, while maintaining a Buy rating. Leerink also adjusted its outlook, increasing its price target to $80 from $70. This adjustment followed the company’s Investor Day, where management provided projections indicating revenue could reach approximately $1 billion by fiscal year 2031. The long-term projection underscores management’s confidence in scaling operations within the DNA synthesis infrastructure space.
Canaccord Genuity initiated coverage on Twist Bioscience with a Buy rating and set a price target of $90. The firm cited the company’s innovative silicon-based lab-on-a-chip technology as a key differentiator. Similarly, Piper Sandler began coverage with an Overweight rating and an $85 price target, emphasizing the company’s critical role in DNA synthesis infrastructure amid growing AI applications. TD Cowen further raised its price target to $89 from $68, citing Twist Bioscience’s strategic positioning to meet increasing AI-driven demands. These developments highlight a positive outlook from various analyst firms regarding the company’s advancements and market opportunities.
Market data indicates TWST closed at $90.35, reflecting a change of -$0.28 or -0.31%. After-hours trading showed a price of $89.65, representing a change of -$0.70 or -0.77%. The stock’s performance over various timeframes, including 1-day, 1-week, 1-month, 6-month, 1-year, 5-year, and maximum periods, is tracked to provide context for investors evaluating the security.
InvestingPro’s AI-picked strategies include TWST, evaluating it against thousands of alternatives using over 100 financial metrics. The platform identifies opportunities by comparing performance metrics across sectors, noting that stocks like Siemens Energy and Sandisk have shown significant gains. The analysis prompts investors to consider whether TWST presents a similar opportunity or if other assets in the same space offer better risk-adjusted returns.